{"id":995396,"date":"2026-08-14T08:09:41","date_gmt":"2026-08-14T12:09:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-provides-business-update-and-reports-second-quarter-2026-financial-results\/"},"modified":"2026-08-14T08:09:41","modified_gmt":"2026-08-14T12:09:41","slug":"pavmed-provides-business-update-and-reports-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pavmed-provides-business-update-and-reports-second-quarter-2026-financial-results\/","title":{"rendered":"PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Veris Health accelerated its commercial engagement with OSU-The James<\/i>\n <\/p>\n

\n Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission<\/i>\n <\/p>\n

\n Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard<\/i>
\n
\n \u00ae<\/sup>
\n <\/i>\n <\/p>\n

\n Conference call and webcast to be held today, August 14, at 8:30 AM EDT<\/i>\n <\/p>\n

\n NEW YORK<\/span>, Aug. 14, 2026<\/span> \/PRNewswire\/ — PAVmed Inc.<\/a>\u00a0(NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”), Veris Health Inc. (“Veris”), and Octeris Medical Inc. (“Octeris”), and reported financial results for the second quarter ended June 30, 2026.<\/p>\n

\n

\n \"PAVmed\n <\/p>\n<\/p><\/div>\n

\n Conference Call and Webcast<\/b>\n <\/p>\n

The\u00a0webcast\u00a0will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com<\/a>.\u00a0 Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed Business Update” to join.<\/p>\n

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.<\/p>\n

\n Business Update Highlights<\/b>\n <\/p>\n

“PAVmed saw tangible progress across its core businesses during this past quarter and recent weeks,” said Lishan Aklog, M.D.<\/a>, PAVmed’s Chairman and Chief Executive Officer. “Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones.”<\/p>\n

\n Highlights from the second quarter and recent weeks<\/b>:<\/p>\n